Literature DB >> 16047350

Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation.

Timothy D Jones1, John N Eble, Mingsheng Wang, Gregory T Maclennan, Shashi Jain, Liang Cheng.   

Abstract

BACKGROUND: Approximately 5% of clear cell renal cell carcinomas contain components with sarcomatoid differentiation. It has been suggested that the sarcomatoid elements arise from the clear cell tumors as a consequence of clonal expansions of neoplastic cells with progressively more genetic alterations. Analysis of the pattern of allelic loss and X-chromosome inactivation in both the clear cell and sarcomatoid components of the same tumor allows assessment of the genetic relationship of these tumor elements.
METHODS: The authors of the current study examined the pattern of allelic loss in clear cell and sarcomatoid components of renal cell carcinomas from 22 patients who had tumors with both components. DNA samples were prepared from formalin-fixed, paraffin-embedded renal tissue sections using laser-capture microdissection. Five microsatellite polymorphic markers for putative tumor suppressor genes on 5 different chromosomes were analyzed. These included D3S1300 (3p14), D7S522 (7q31), D8S261 (8p21), D9S171 (9p21), and TP53 (17p13). In addition, X-chromosome inactivation analysis was performed in 14 tumors from female patients.
RESULTS: The clear cell components showed loss of heterozygosity (LOH) at the D3S1300, D7S522, D8S261, D9S171, and TP53 loci in 18% (4/22), 18% (4/22), 50% (10/20), 15% (3/20), and 20% (4/20) of informative cases, respectively. LOH in the sarcomatoid components was seen at the D3S1300, D7S522, D8S261, D9S171, and TP53 loci in 18% (4/22), 41% (9/22), 70% (14/20), 35% (7/20), and 20% (4/20) of informative cases, respectively. Six cases demonstrated an LOH pattern in the clear cell component that was not seen in the sarcomatoid component. Different patterns of allelic loss were seen in the clear cell and sarcomatoid components in 15 cases. Clonality analysis showed the same pattern of nonrandom X-chromosome inactivation in both clear cell and sarcomatoid components in 13 of the 14 cases studied. One case showed a random pattern of X-chromosome inactivation.
CONCLUSION: X-chromosome inactivation analysis data suggest that both clear cell and sarcomatoid components of renal cell carcinomas are derived from the same progenitor cell. Different patterns of allelic loss in multiple chromosomal regions were observed in clear cell and sarcomatoid components from the same patient. This genetic heterogeneity indicates genetic divergence during the clonal evolution of renal cell carcinoma. Copyright 2005 American Cancer Society.

Entities:  

Mesh:

Year:  2005        PMID: 16047350     DOI: 10.1002/cncr.21288

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  31 in total

1.  The clinical, research, and social value of autopsy after any cancer death: a perspective from the Children's Oncology Group Soft Tissue Sarcoma Committee.

Authors:  Sheri L Spunt; Sara O Vargas; Cheryl M Coffin; Stephen X Skapek; David M Parham; Joan Darling; Douglas S Hawkins; Charles Keller
Journal:  Cancer       Date:  2011-10-17       Impact factor: 6.860

Review 2.  Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art.

Authors:  Cedric Lebacle; Aydin Pooli; Thomas Bessede; Jacques Irani; Allan J Pantuck; Alexandra Drakaki
Journal:  World J Urol       Date:  2018-06-01       Impact factor: 4.226

3.  Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer.

Authors:  Barbara Domazet; Gregory T Maclennan; Antonio Lopez-Beltran; Rodolfo Montironi; Liang Cheng
Journal:  Int J Clin Exp Pathol       Date:  2008-03-15

Review 4.  The role of proteomics in the age of immunotherapies.

Authors:  Sarah A Hayes; Stephen Clarke; Nick Pavlakis; Viive M Howell
Journal:  Mamm Genome       Date:  2018-07-25       Impact factor: 2.957

5.  Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components.

Authors:  Brandon J Manley; James J Hsieh
Journal:  Transl Cancer Res       Date:  2016-08       Impact factor: 1.241

6.  Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy.

Authors:  Brian Shuch; Jonathan Said; Jeffrey C LaRochelle; Ying Zhou; Gang Li; Tobias Klatte; Frederic Pouliot; Fairooz F Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Journal:  Cancer       Date:  2010-02-01       Impact factor: 6.860

7.  High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment.

Authors:  Eril J Kouba; John N Eble; Novae Simper; David J Grignon; Mingsheng Wang; Shaobo Zhang; Lisha Wang; Guido Martignoni; Sean R Williamson; Matteo Brunelli; Claudio Luchini; Anna Calió; Liang Cheng
Journal:  Mod Pathol       Date:  2016-07-29       Impact factor: 7.842

8.  Stability of preclinical models of aggressive renal cell carcinomas.

Authors:  Mariana Varna; Guilhem Bousquet; Irmine Ferreira; Marie Goulard; Morad El-Bouchtaoui; Pierre Mongiat Artus; Jérome Verine; Eric de Kerviler; Lucie Hernandez; Christophe Leboeuf; Bernard Escudier; Luc Legrès; Niclas Setterblad; Hany Soliman; Jean-Paul Feugeas; Anne Janin; Philippe Bertheau
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

9.  Extensive peritoneal carcinomatosis secondary to renal cell carcinoma with sarcomatoid and rhabdoid differentiation.

Authors:  Ashwini K Esnakula; Tammey J Naab; William Green; Babak Shokrani
Journal:  BMJ Case Rep       Date:  2013-04-22

Review 10.  From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma.

Authors:  Androu Arsanious; Georg A Bjarnason; George M Yousef
Journal:  Mol Cancer       Date:  2009-03-17       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.